Home - Syenza News

Latest

The European Federation of Pharmaceutical Industries and Associations (EFPIA) has published recommendations for the European Union's next Multiannual Financial Framework (MFF) for 2028-2034. In this publication, EFPIA outlines that the future MFF should support the life sciences research and inno...

Latest

This update presents updates of the NICE health technology evaluations manual (PMG36). Key points include broad engagement with patient groups, industry, and academic experts. The focus is on proposed methods for incorporating patient perspectives, addressing health inequalities, and refining eco...

Latest

The Canada Drug Agency Plan has recently launched its first five-year strategic initiative, "Insight to Impact 2025-2030." This milestone reflects the agency's evolution from its previous identity as the Canadian Agency for Drugs and Technologies in Health (CADTH). The plan outlines a vision for ...

Global Updates

The VIETNARMS trial provides significant insights into hepatitis C treatment options, particularly in evaluating WHO-recommended first-line therapies. It also explores alternative treatment strategies. This groundbreaking study has the potential to reshape our understanding of effective treatment...

Global Updates

The economic ramifications of hepatitis C (HCV) are staggering. Estimates suggest the disease could impose a $1.17 trillion burden on China from 2023 to 2050. This is the crux of the hepatitis C investment impact article we cover below, meeting WHO's 2030 HCV diagnosis and treatment targets requi...

Global Updates

Bulevirtide HDV therapy has shown remarkable promise in Gilead's final results from the Phase 3 MYR301 study. The findings indicate that longer bulevirtide monotherapy for chronic hepatitis delta virus (HDV) leads to sustained virologic suppression after stopping treatment. Notably, 36% of adults...

Global Updates

The FDA AI Drug Approval initiative marks a significant milestone as the FDA completes its first pilot of generative AI aimed at enhancing scientific reviews. This aggressive plan to fully deploy AI technology across all FDA centers by June 30, 2025, will improve the approval process for new ther...

Europe

EFPIA Advocates for Stronger Life Sciences in EU Multiannual Financial Framework

May 16, 2025 João L. Carapinha

💡 How can the EU strengthen its pharmaceutical sector for the future?

The EFPIA has laid out critical recommendations for the next EU Multiannual Financial Framework (2028-2034), focusing on boosting funding for life sciences research, enhancing regulatory competitiveness, and improving health data infrastructure. These insights could significantly shape the future landscape of healthcare in Europe.

Dive into the full article to learn how these recommendations aim to propel innovation and increase access to medicines across Europe!

#SyenzaNews #pharmaceuticals #healthcarepolicy

Evolving NICE Health Technology Evaluations: Enhancing Patient Perspectives and Addressing Health Inequalities

May 15, 2025May 15, 2025 João L. Carapinha

Bulevirtide HDV Therapy: Promising Results in Durable Virologic Control

May 12, 2025 João L. Carapinha

FDA AI Drug Approval

May 9, 2025 João L. Carapinha

Middle East

Hepatitis C Investment Impact: Maximizing Health and Economic Returns in China

May 14, 2025 João L. Carapinha

💰 What could a staggering $1.17 trillion economic toll mean for the future of healthcare in China?

This article reviews the economic impacts of hepatitis C and highlights how an investment of $69.72 billion could prevent over a million deaths and unlock significant societal gains. Accelerating efforts to meet WHO targets isn’t just a health imperative – it’s a financial opportunity we can’t afford to overlook.

Explore the insights and find out how transformative investments can reshape the landscape of health and economics.

#SyenzaNews #HealthEconomics #HealthcarePolicy #CostEffectiveness

Implementing Health Technology Assessment in Oman

May 6, 2025May 6, 2025 João L. Carapinha

AI Patient Education: Evaluating ChatGPT and Gemini for Pediatric Condition Materials

April 22, 2025April 22, 2025 João L. Carapinha

Advancing Early Childhood Health: PureHealth’s Partnership with Abu Dhabi Authority

April 14, 2025 João L. Carapinha

Sub-Saharan Africa

South Africa NHI Bill Court Ruling Calls for Scrutiny

May 7, 2025May 7, 2025 Rene Pretorius

🔍 What does a recent court ruling mean for South Africa’s healthcare system?

This pivotal decision from the Gauteng High Court mandates President Cyril Ramaphosa to justify his signing of the National Health Insurance Bill, opening the door for judicial review of executive decisions in healthcare legislation. As the implications of this ruling unfold, it reflects a significant check on executive power, particularly in contentious policy areas.

Curious to learn more about the potential impact on the NHI Act and South Africa’s healthcare future? Dive into the full article for comprehensive insights!

#SyenzaNews #HealthcarePolicy #HealthTech #Governance

Syenza's Top Picks

Journavx Market Access Strategy in Focus: What Early Payer Decisions Signal for Future Launches

FDA Warning Aspen Pharmacare: Evaluating Compliance Violations and Their Impact

Lenacapavir HIV Prevention: Approval and Access Strategy Updates

Journavx Pain Management: FDA Approves New Non-Opioid Treatment for Acute Pain

NovoCare and the Rise of Direct-to-Consumer Pharmaceutical Access

Zircaix: A Potential Breakthrough in Kidney Cancer Diagnosis

Dialysis Technology Innovations: Revolutionizing Patient Care with Portable Solutions

Latest

Latest

Latest

Latest

Join Our LinkedIn Groups

Global Updates

Global Updates

Global Updates

Global Updates

Europe

Middle East

Sub-Saharan Africa

When you partner with Syenza, it’s like a Nuclear Fusion.